Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials (Q38599514)

4 September 2017

Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials (English)

1 reference

4 September 2017

phase I clinical trial

0 references

0 references

1 reference

1 reference

4

0 references

author name string

Selidji T Agnandji

series ordinal

1

1 reference

PubMed ID

26437872

4 September 2017

José F Fernandes

series ordinal

2

1 reference

PubMed ID

26437872

4 September 2017

Emmanuel B Bache

series ordinal

3

1 reference

4 September 2017

6 October 2015

1 reference

4 September 2017

26

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

4 September 2017

10

1 reference

4 September 2017

1553-1578

1 reference

4 September 2017

10

1 reference

From the circumsporozoite protein to the RTS, S/AS candidate vaccine

4 September 2017

1 reference

Unexpected fold in the circumsporozoite protein target of malaria vaccines

21 January 2018

1 reference

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

21 January 2018

1 reference

Vaccine adjuvants: putting innate immunity to work

21 January 2018

1 reference

A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults.

21 January 2018

1 reference

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

21 January 2018

1 reference

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

21 January 2018

1 reference

Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein-based vaccine.

21 January 2018

1 reference

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

21 January 2018

1 reference

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

21 January 2018

1 reference

Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children

21 January 2018

1 reference

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

21 January 2018

1 reference

Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.

21 January 2018

1 reference

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

21 January 2018

1 reference

Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children

21 January 2018

1 reference

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

21 January 2018

1 reference

Protective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF-α producing effector and central memory CD4 T cells

21 January 2018

1 reference

Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial

21 January 2018

1 reference

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

21 January 2018

1 reference

Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.

21 January 2018

1 reference

Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial

21 January 2018

1 reference

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

21 January 2018

1 reference

A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon

21 January 2018

1 reference

Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D)

21 January 2018

1 reference

Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children

21 January 2018

1 reference

T cell responses to the RTS,S/AS01e and RTS,S/AS02D malaria candidate vaccines administered according to different schedules to Ghanaian children

21 January 2018

1 reference

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

21 January 2018

1 reference

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial

21 January 2018

1 reference

Evaluation of the safety and immunogenicity of the RTS,S/AS01 E malaria candidate vaccine when integrated in the expanded program of immunization

21 January 2018

1 reference

Safety and efficacy of the RTS, S/AS01 E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial

21 January 2018

1 reference

Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults

21 January 2018

1 reference

Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites

21 January 2018

1 reference

Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia

21 January 2018

1 reference

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.

21 January 2018

1 reference

Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children

21 January 2018

1 reference

The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants

21 January 2018

1 reference

Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial

21 January 2018

1 reference

Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region

21 January 2018

1 reference

Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia

21 January 2018

1 reference

Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria

21 January 2018

1 reference

Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique

21 January 2018

1 reference

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research

21 January 2018

1 reference

A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease.

21 January 2018

1 reference

Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine

21 January 2018

1 reference

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.

21 January 2018

1 reference

Further analysis of correlates of protection from a phase 2a trial of the falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults.

21 January 2018

1 reference

A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E

21 January 2018

1 reference

The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection

21 January 2018

1 reference

Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure

21 January 2018

1 reference

Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children

21 January 2018

1 reference

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children

21 January 2018

1 reference

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

21 January 2018

1 reference

Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data

21 January 2018

1 reference

RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection

21 January 2018

1 reference

Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.

21 January 2018

1 reference

Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data

21 January 2018

1 reference

Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trials

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FMB.15.90

1 reference

4 September 2017

1 reference

PubMed ID

26437872